Literature DB >> 16923427

The p22phox C242T gene polymorphism is associated with a reduced risk of angiographically verified coronary artery disease in a high-risk Finnish Caucasian population. The Finnish Cardiovascular Study.

Meng Fan1, Mika Kähönen, Riikka Rontu, Rami Lehtinen, Jari Viik, Mari Niemi, Tuomo Nieminen, Kari Niemelä, Ilkka Pörsti, Tiit Kööbi, Väinö Turjanmaa, Terho Lehtimäki.   

Abstract

BACKGROUND: Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is a major source of the superoxide anion, which may play an important role in the development of atherosclerosis and coronary artery disease (CAD). The p22phox, a component of the NADPH oxidase, is essential for the activation of this enzyme, and intensive expression of the p22phox has been reported in human atherosclerotic arteries. However, studies on the association of the C242T polymorphism in the p22phox gene with CAD have produced conflicting results, and the relation of this polymorphism with CAD is not well known in a population with acquired risk factors enhancing the NADPH-dependent superoxide production.
METHODS: As part of the Finnish Cardiovascular Study, a case-control study was conducted with 402 high-risk Finnish Caucasian patients undergoing coronary angiography. Genotyping was performed using the 5' nuclease TaqMan assay.
RESULTS: The prevalence of the T allele (TT + TC genotypes) was significantly lower among angiographically verified CAD patients (n = 250) than among control subjects (n = 152, P = .013). In contrast to subjects with the CC genotype, the T allele was found protective against CAD (odds ratio = 0.531, 95% CI 0.331-0.852, P = .009), and the results remained significant after adjustment for other significant coronary risk factors.
CONCLUSIONS: The T allele in the C242Tpolymorphism of the p22phox gene had a protective effect against the development of CAD despite the exposure of study subjects to risk factors related to excessive NADPH-dependent superoxide production.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16923427     DOI: 10.1016/j.ahj.2006.02.018

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

1.  C242T polymorphism of NADPH oxidase p22phox gene reduces the risk of coronary artery disease in a random sample of Egyptian population.

Authors:  Ingy M Hashad; Mohamed F Abdel Rahman; Sahar M Abdel-Maksoud; Khalda S Amr; Laila K Effat; Gamal M Shaban; Mohamed Z Gad
Journal:  Mol Biol Rep       Date:  2014-01-11       Impact factor: 2.316

Review 2.  NADPH oxidases in cardiovascular disease: insights from in vivo models and clinical studies.

Authors:  Alexander Sirker; Min Zhang; Ajay M Shah
Journal:  Basic Res Cardiol       Date:  2011-05-20       Impact factor: 17.165

3.  The C242T polymorphism of the p22-phox gene (CYBA) is associated with higher left ventricular mass in Brazilian hypertensive patients.

Authors:  Roberto Schreiber; Maria C Ferreira-Sae; Juliana A Ronchi; José A Pio-Magalhães; José A Cipolli; José R Matos-Souza; José G Mill; Aníbal E Vercesi; José E Krieger; Kleber G Franchini; Alexandre C Pereira; Wilson Nadruz Junior
Journal:  BMC Med Genet       Date:  2011-08-31       Impact factor: 2.103

4.  Polymorphisms of C242T and A640G in CYBA gene and the risk of coronary artery disease: a meta-analysis.

Authors:  Qiumei Xu; Fangfen Yuan; Xuemei Shen; Hui Wen; Wei Li; Bei Cheng; Jing Wu
Journal:  PLoS One       Date:  2014-01-02       Impact factor: 3.240

5.  No difference in genotype frequencies of polymorphisms of the nitric oxide pathway between Caucasian normal and high tension glaucoma patients.

Authors:  Johanna Weiss; Stephan A Fränkl; Josef Flammer; Matthias C Grieshaber; Gabor Hollo; Barbara Teuchner; Walter Emil Haefeli
Journal:  Mol Vis       Date:  2012-08-07       Impact factor: 2.367

6.  Relationship of the p22phox (CYBA) gene polymorphism C242T with risk of coronary artery disease: a meta-analysis.

Authors:  Zhijun Wu; Yuqing Lou; Wei Jin; Yan Liu; Lin Lu; Qiujing Chen; Yucai Xie; Guoping Lu
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.